American Society for Virology

KaliVir Immunotherapeutics Appoints Viral Immunotherapy Researcher Grant McFadden, Ph.D., to its Board of Directors

Retrieved on: 
Wednesday, May 10, 2023
Royal, Jennerex, IMV, Canadian Academy of Health Sciences, International Committee for the Nanking Safety Zone, Doctor of Philosophy, Taxonomy, American Academy, American Society for Virology, Science, Smallpox, Arizona State University, JD, Immune system, Outline of health sciences, McGill University, Knowledge, Growth, Grant, Research, Therapy, Vaccine, McFadden, Society, Royal Society, Virotherapy, Immunotherapy, Virus, Virology, Biochemistry

PITTSBURGH, May 10, 2023 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc. , a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the appointment of Grant McFadden, Ph.D., to its Board of Directors.

Key Points: 
  • PITTSBURGH, May 10, 2023 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc. , a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the appointment of Grant McFadden, Ph.D., to its Board of Directors.
  • McFadden is the director of the Biodesign Center for Immunotherapy, Vaccines and Virotherapy and a Professor at Arizona State University.
  • He was co-founder and Board member of OncoMyx Therapeutics and has served on advisory boards for numerous companies including Jennerex, DNAtrix and IMV.
  • "KaliVir has exciting technology and a stellar team and I am honored to join its Board of Directors as the company progresses its first candidate into the clinic," said McFadden.

Thylacine Biotherapeutics Licenses Novel Antiviral Peptide Platform from Columbia University

Retrieved on: 
Tuesday, February 14, 2023
SARS, SARS-CoV-2, Lower respiratory tract infection, American Society for Virology, MERS, Columbia University, Host–pathogen interaction, Peptide, Invention, Disease, Infection, Society, COVID-19, Virology, Doctor of Philosophy, MD, Vaccine

NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Thylacine Biotherapeutics Inc. ("Thylacine Bio"), a privately held biotech company dedicated to combating infectious disease, announced today it has entered into a license agreement with Columbia University ("Columbia") for worldwide exclusive rights to develop and commercialize a novel antiviral peptide platform.

Key Points: 
  • NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Thylacine Biotherapeutics Inc. ("Thylacine Bio"), a privately held biotech company dedicated to combating infectious disease, announced today it has entered into a license agreement with Columbia University ("Columbia") for worldwide exclusive rights to develop and commercialize a novel antiviral peptide platform.
  • This new platform addresses pathogens within 8 RNA virus families identified as likely sources of the next pandemic.
  • Leading virologists, Matteo Porotto, PhD and Anne Moscona, MD, President-Elect of the American Society for Virology, of Columbia's Center for Host Pathogen Interaction, invented and refined this antiviral platform.
  • "We are thrilled to work with the world-class scientists of the Moscona-Porotto lab at Columbia University on this groundbreaking antiviral platform," said Elma Hawkins, PhD, Thylacine Bio's Executive Chair.

PDS Biotech Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 8, 2022
Risk, ASCO, Trial of the century, GLOBE, ORR, SEC, Business development, Clinical trial, Research, Communication, Patient, Pembrolizumab, International, CPI, Biotechnology, Infection, Animal, Food, National Cancer Institute, Merck Sharp & Dohme Federal Credit Union, Annual general meeting, Merck, General counsel, Merck & Co., Nature, Immunotherapy, Webcast, Nasdaq, PDS, United Kingdom, Forward-looking statement, Senior, American Society of Clinical Oncology, American Society for Virology, Neoplasm, COVID-19, Vaccine, Food and Drug Administration, Goal, COBRA, FDA, Population, Society, Sharp, Review, PDSB, Company, Twitter, Therapy, Pharmaceutical industry, Cryptocurrency, H1N1

Strengthened leadership team with addition of Spencer Brown as Senior Vice President and General Counsel, and Sanjay Zaveri as Senior Vice President, Business Development.

Key Points: 
  • Strengthened leadership team with addition of Spencer Brown as Senior Vice President and General Counsel, and Sanjay Zaveri as Senior Vice President, Business Development.
  • With these data, we are hopeful that our upcoming meetings with the FDA will clarify our regulatory path forward for PDS0101.
  • PDS Biotechs cash balance as of June 30, 2022 was approximately $53.0 million.
  • The event will be archived in the investor relations section of PDS Biotechs website for six months.

PDS Biotechnology Announces Presentation of Universal Flu Vaccine Preclinical Data at the 41st American Society of Virology Meeting

Retrieved on: 
Thursday, July 14, 2022
Goal, SEC, World, Center, Society, Communication, COBRA, Infection, Immunology, Vaccine, Animal, Neck, Lung, Colon, Ted Ross, Company, National Institute of Allergy and Infectious Diseases, Survival, Prostate, Review, American Society for Virology, University of Georgia, MD, GLOBE, Virology, COVID-19, NIAID, University of Kentucky College of Medicine, Breast, Biotechnology, Cancer, Nasdaq, Civics, Risk, PDSB, Forward-looking statement, World Health Organization, Antigen, Head, Research, University, Twitter, DRS, Survival rate, Immunotherapy, Immune system, Nature, 40, National Institute, H1N1

The study demonstrated that the investigational universal flu vaccine was effective against multiple strains of the influenza virus.

Key Points: 
  • The study demonstrated that the investigational universal flu vaccine was effective against multiple strains of the influenza virus.
  • Infectimuneallowed for significant dose-sparing with effective protection demonstrated using 25-fold lower doses of the COBRA antigens in animals.
  • Currently, there is no universal vaccine that provides broad protection against multiple strains of influenza.
  • These data suggest that PDS0202 has the potential to achieve the goal of providing the broad protection sought in a universal influenza vaccine.